Physician profile
Egdar Ramos
NPI 1346336823
$1,121.57
in general payments reported to CMS, 2019-2025
10 companies · $407 in 2025
The $407 reported for 2025 was more than what 76% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.04 · 2022: $65.92 · 2023: $189 · 2024: $405 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.61 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $356.51 | 2023-2025 | Avvigo Guidance System, Rotapro, Accolade Sr |
| Shockwave Medical, INC | $265.41 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Abbott Laboratories | $149.29 | 2022-2025 | Dragonfly Opstar, Ensite |
| Medtronic, INC. | $107.20 | 2025 | Micra |
| Pfizer INC. | $96.70 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.04 | 2021 | |
| Chiesi USA, INC. | $30.71 | 2024-2025 | Kengreal |
| Terumo Medical Corporation | $28.69 | 2025 | Glidesheath Slender, Tr Band |
| Janssen Pharmaceuticals, INC | $18.98 | 2024 | Xarelto |
| Abiomed | $14.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Egdar Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.